ABSTRACT

BACKGROUND AND OBJECTIVES: Pain evaluation and the choice of the analgesic best providing its control are extremely important for patients’ quality of life. This study aimed at describing the characteristics which make meperidine unfeasible for pain management, at calling the attention to the incidence of its prescriptions and to the need of a multidisciplinary educative action aiming at decreasing its use, in addition to presenting two opioids as options for analgesia.

CONTENTS: National or international scientific and governmental publications between the years 1997 and 2013 used in this study report that meperidine is not indicated for pain management, primarily due to its short action time, presence of neurotoxic metabolite (normeperidine) and possibility of rapidly developing tolerance.

CONCLUSION: According to analyzed data, meperidine was the most widely used opioid for analgesia or was among the most prescribed analgesics. This fact shows the real need for an educative multidisciplinary action to promote awareness of meperidine risks and to decrease its prescription. According to searched literature, morphine and methadone have longer action time and higher analgesic potency, with metabolites which are less toxic and noxious for patients as compared to meperidine.

Keywords: Analgesia, Meperidine, Methadone, Morphine, Pain.

INTRODUCTION

Pain is defined as sensory, emotional, subjective, personal and unpleasant experience related to real or potential tissue injury.

Pain evaluation is critical for its adequate control, since several studies have shown that non-relieved pain limits individuals in their daily activities, changes mood, exacerbates pain fear, thus affecting the quality of life (QL) of patients and their caregivers.

The World Health Organization (WHO) recommends strong opioids to manage acute or severe chronic pain, associated or not to non-opioids, adjuvants or non-pharmacological techniques, aiming at improving pain and QL.

Meperidine is a strong opioid, however due to some unique features WHO itself and the authors of national and international articles or governmental publications published between 1997 and 2013 utilized in this study report that meperidine is not recommended for analgesia and suggest its replacement by other opioids.

This study aimed at defining the features which make meperidine unfeasible for pain management, at calling the attention for the incidence of its prescription and the importance of a multidisciplinary educative action to decrease its use, since there is the option of other strong opioids with less toxicity, in addition to introducing morphine and methadone as options for analgesia.
CONTENTS

Meperidine (or petidine) is a synthetic opioid which, for being structurally similar to morphine, atropine, cocaine and histamine, has several pharmacological effects, such as analgesic, spasmolytic, general anesthesia and mild anti-histaminic activity. It acts by binding to Mu (μ) and Kappa (κ) opioid receptors, being 10 times less potent than morphine.

Meperidine administration route is primarily intramuscular, but it is also well absorbed in the gastrointestinal tract; its action lasts from two to four hours being biotransformed in the liver where, by the N-demethylation process, forms its primary metabolite, normeperidine (or norpetidine), and is excreted by the urine.

Normeperidine half-life is between 14 and 21h, it has twice more stimulating effects which potentially toxic in the central nervous system (CNS) and has just half the analgesic properties of meperidine.

After meperidine administration, due to its short action time, painful sensation reappears and a new dose is necessary, however normeperidine produced as from the first dose will add to that of the second dose, and so on. By the cumulative effect and due to its long plasma half-life, this metabolite may reach dangerously toxic levels.

Prolonged administration results in normeperidine buildup, which is hepatotoxic, and acts stimulating the CNS generating myoclonus, delirium, more severe psychomotor agitation and seizures.

There may be meperidine metabolites buildup in patients with kidney or liver failure.

Among major reasons for using meperidine there are its easy availability, short action time, for not inducing miosis and also due to the belief that such short-action opioid will cause less dependence.

Physical dependence and withdrawal symptoms are as severe as those of morphine. However, in early dependence, reports that after just some few doses there is already an imperious will of not living without this opioid, together with more severe intoxication symptoms, make meperidine a more hazardous drug for the development of tolerance and addiction.

Garcia & Santos report that several authors mention the drug addiction potential with the use of meperidine and mention a study evaluating hospital admission cases due to dependence, which had the following results: 457 admittedly meperidine addicted individuals, of whom 288 have become dependent after contact with this opioid without previous use of any other substance.

For acute pain management, when morphine muscarinic effects are not desirable, meperidine may erroneously be the drug of choice. Some authors advocate meperidine as the best solution to control shivering at the end of surgical and anesthetic procedures, however, this shivering may be prophylactically prevented by directly warming part of the body and the surgical bed with thermal mattresses and blankets and by maintaining operating room temperature between 21º and 24º C.

During the 1980s, the follow-up of meperidine complications has recommended lowered total daily dose, especially in situations where repeated doses were prescribed, and since in following years science was unable to establish safe levels for this opioid, not even for young adults with normal kidney functions, several authors started to advocate the non-prescription of meperidine.

The International Association for the Study of Pain (IASP), the WHO and other entities recommend restricted use of meperidine to manage acute pain and its replacement, whenever possible, by other less toxic opioids; and strongly condemn its use to manage chronic pain, which in addition to toxicity may also induce chemical dependence because the development of tolerance to meperidine is very fast and may appear even with a single dose.

However, this restriction or replacement seems not to be occurring because available studies report excessive meperidine consumption in Brazilian and other developing countries.

A study has observed meperidine and morphine prescription profile in a hospital and has concluded that the most frequently used opioid was meperidine, being present in 90% of evaluated prescriptions, especially to manage postoperative pain.

According to data of the II Home Survey on the use of Psychotropic Drugs in Brazil in 2005, meperidine was the second most used opioid reported by respondents.

According to Moura, Ribeiro & Magalhães report, meperidine is among the 10 most prescribed opioids in the studied hospital.

In the study by Calil & Pimenta, addressing relationships between analgesic pattern and trauma severity, meperidine was the most prescribed opioid, being present in 10.4% of all analgesic prescriptions.

A study has observed pain incidence in cosmetic surgeries and analgesia and has concluded that the most prescribed analgesic was meperidine.

In their studies, Souza & Alves Neto have evaluated physicians’ knowledge about pain management and their analgesic approaches and have shown that a high percentage of physicians (29.57%) used meperidine.

A study aiming at understanding nurses perception about opioid administration for non-malignant chronic pain relief has observed that a relevant number of nurses (26.7%) has mentioned meperidine as an opioid to relief such pain.

Among currently used opioids for labor analgesia, meperidine is the most widely used and studied. In most studies, meperidine shows a certain level of analgesia, however in a large number of cases it has insufficient response, leading some authors to suggest that it acts much more as sedative than as analgesic. There is also a report of adverse effects, such as mother nausea, vomiting and dizziness or neonate respiratory depression.

In addition to delivery, one should also pay attention to breastfeeding, because since meperidine has a long half-life...
active metabolite, the dose excreted in the milk may buildup in the infant causing behavioral depression, difficulty to suck breast milk or seizure. According to a study, meperidine may be replaced by morphine as post-delivery analgesic, because morphine has a higher analgesic power and induces less sedation. In addition, the concentration of its metabolite in the milk is considered compatible with breastfeeding.

The percentage of meperidine prescription as compared to the prescription of other opioids during hospital stay is used as hospital quality standard and accreditation in developed countries, being accepted up to 20% of meperidine prescription among total opioids in emergency settings, and up to 10% for hospitalization sectors, being that in institutions where these percentages are exceeded, physicians receive therapeutic update courses with emphasis meperidine.

The implementation of the educational multidisciplinary protocol to decrease meperidine prescription in the Israelite Hospital Albert Einstein was effective because it has significantly contributed to decrease its consumption.

In 2006, the Ministry of Health has recommended the exclusion of meperidine from the National List of Essential Drugs (RENAME) due to the presence of the neurotoxic metabolite normeperidine, its short action time and for being three times more expensive than morphine without having therapeutic advantages.

Morphine acts as exogenous agonist of Mu (μ), Kappa (κ) and Delta (δ) opioid receptors, being considered the standard of all central action analgesics and used to manage severe chronic and acute pain.

Morphine has action duration of four to six hours, half-life of three to four hours, being biotransformed in the liver and originating metabolites: morphine-3-glucuronide and morphine-6-glucuronide.

Morphine-3-glucuronide is considered inactive due to poor affinity with opioid receptors. Morphine-6-glucuronide is considered active with plasma half-life of two hours, being a potent μ receptors agonist, which may contribute to morphine analgesic effect.

There may be morphine metabolites buildup in patients with kidney failure. Oral morphine is less potent than injectable morphine because the absorption is fast and incomplete, being soon metabolized and obtaining approximately 1/5 to 1/3 of plasma concentration reached by injectable parenteral route, so infusion pumps or scheduled release capsules may be used aiming at patients’ wellbeing.

Plummer et al. results have indicated that morphine was more effective to control postoperative pain as compared to meperidine.

In a systematic review, most authors use morphine as first line opioid and methadone as second option. Methadone is a synthetic opioid agonist of Mu, Delta and Kappa opioid receptors and antagonist of N-methyl-D-aspartate (NMDA) receptors. It was initially used to prevent and control opioid withdrawal syndrome, which has stigmatized it, creating a certain resistance to its use as analgesic. Oral methadone absorption is fast and almost complete. Its analgesic effect, with is five to ten times higher than morphine, in general lasts for six to eight hours. Primary methadone metabolites, “EDDP” (2-ethylene-1,5 dimethyl 3-3 diphenylpyrrolidine) and “EMDP” (2 ethyl 5 methyl 3-3 diphenyl pyrroline) are inactive and excreted especially by feces, and urine, being that renal excretion decreases along time allowing its use in patients with chronic kidney disease. Methadone should be carefully prescribed due to its long plasma half-life of 13 to 50h, needing frequent follow up and gradual dose evolution, if needed, until the effective dose is found. Methadone induces less nausea, constipation and sedation as compared to morphine and its euphorizing effect and psychic and physical dependence rates are lower as compared to other opioids.

Salamonde et al. have observed patient controlled analgesia at home with methadone and have concluded that this opioid is a safe and effective option, not inducing significant side effects. Ribeiro, Schmidt & Schmid have reported that methadone may be an option to treat chronic pain, especially in the presence of neuropathic pain, due to antagonism on NMDA receptor. In this study, authors have also stated that methadone is effective and safe to treat cancer-related painful syndromes.

Table 1 was structured based on researched information and shows meperidine features which make unfeasible its use to manage pain, and helps the relationship and comparison with the options of studied opioids: morphine and methadone.

<table>
<thead>
<tr>
<th>Action time</th>
<th>Analgesic potency</th>
<th>Features of major metabolites</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meperidine</td>
<td>Morphine</td>
<td>Methadone</td>
</tr>
<tr>
<td>2 to 4 hours</td>
<td>10 times lower than morphine</td>
<td>4 to 6 hours Comparison standard</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Morphine-3-glucuronide: inactive</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Morphine-6-glucuronide: Um receptor agonist, contributing to analgesia, with half-life of 14 to 21 hours.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EDDP and EMDP: Inactive</td>
</tr>
</tbody>
</table>

**CONCLUSION**

It was observed that meperidine is not indicated to manage pain; however, according to data of analyzed studies, it was the most widely prescribed opioid, or was among the most indicated or used analgesics. This fact calls the attention to the need of a multidisciplinary education of pharmacists, physicians and nurses, aiming at the awareness of the risks of meperidine use and at decreasing its prescription, limiting its administration to cases where other options were not effective of feasible.
Morphine and methadone were introduced as alternatives for analgesia. Both opioids, according to data of researched literature, have longer action time and more analgesic potency with less toxic and noxious metabolites as compared to meperidina, allowing a more effective pain management and better quality of life.

REFERENCES